Services for Adults with Learning Difficulties: Hillingdon

Ashley Dalton Excerpts

Friday 4th July 2025 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

I thank my hon. Friend the Member for Uxbridge and South Ruislip (Danny Beales) for securing this debate around services in the community for people with a learning difficulty in Hillingdon, and for championing the rights of people with learning difficulties in his area. I welcome those in the Gallery who are here to demonstrate how important services for people with learning difficulties in Hillingdon are to them. I join my hon. Friend in paying particular tribute to Oliver, Doug, George and Georgia for all their work in this area.

I am aware that, as a member of the Health and Social Care Committee, my hon. Friend has a keen interest in health and social care matters. He will therefore be pleased to know that the Government have today published their response to the Health and Social Care Committee report “Adult Social Care Reform: the cost of inaction”. I am sorry to hear that Hillingdon council has decided to close the Rural Activities Garden Centre, but as Members know, decisions on local services are for councils to make since they are best placed to understand and meet the needs of their local populations.

[John McDonnell]

I fully appreciate the point that the Minister makes, but will she take advice from colleagues in other Departments on the following specific point? My hon. Friend the Member for Uxbridge and South Ruislip (Danny Beales) and I have been working with different groups and we have sought to register, under relevant legislation, the Rural Activities Garden Centre as a community asset, which would force the local authority to properly consult with us and to engage with the wider community. The council is going ahead with the decision to sell or close in advance of even considering whether it should be a community asset. Will she help us by taking advice, from whichever Department is relevant, about whether or not there is anything we can do, as a Government, to ensure that Hillingdon council abides by the legislation that was passed to protect community assets such as this one?

[Ashley Dalton]

I will ensure that that issue is raised with the relevant Department. I will say a little more about some of the expectations we place on local authorities to shape their care markets to meet the diverse needs of all local people, as required under the Care Act 2014.

This Government recognise the vital importance of co-production and working with people who draw on care and support. To ensure local authorities are meeting these duties, the Care Quality Commission are assessing local adult social care services by publishing a full report and overall performance rating for each local authority. Hillingdon has been rated as “Good” in the CQC’s recent assessment, but the report also includes feedback on areas where the CQC concluded that Hillingdon could improve.

It is great to be having this discussion today, on the last day of Co-production Week, an important annual awareness campaign to recognise the benefits of working in equal partnership with people using health and social care provision. Local councils should absolutely involve, engage and consult adults with learning difficulties on their care plans, as well as on wider decisions that affect their care and support, and their lives in general. We are committed to encouraging genuine co-production between social care professionals, local authorities, policymakers and, crucially, people who draw on care and support, to design a system that works better for everyone—one that is fair, inclusive and puts people first.

The Government recognise that investment in local services in the community is vital. That is why we have made available over £69 billion for local government this financial year, increasing core spending power by up to 6.8% in cash terms on last year. For Hillingdon, that means a total of £266.3 million in its core spending power for this year, an increase of 6.2% on 2024-25.

We strongly encourage councils to apply elements of good market-shaping practice involving providers. My hon. Friend the Member for Uxbridge and South Ruislip talked about how people with learning disabilities should be worked with across the Government, but actually that applies to all Government, because we seek to serve the people and that includes people with learning disabilities.

Yesterday, we published our 10-year plan. I am delighted that social care will, for some people, be a key part of the neighbourhood health services we discussed, but the adult social care system is in need of wider reform. We have already begun that journey, including legislating for a fair pay agreement and the independent commission into social care. Over time, the neighbourhood health service and the national care service will work hand-in-hand with each other to help people stay well and live independently.

To conclude, I note my hon. Friend’s invitation to visit Hillingdon and I will ensure that that invitation is extended to the relevant Minister. I once again thank him for bringing forward this important debate, and every Member who has contributed. I hope that Hillingdon council takes notice of this debate.

Question put and agreed to.

NHS 10-Year Plan

Ashley Dalton Excerpts

Thursday 3rd July 2025 Commons Chamber

[Wes Streeting]

My hon. Friend is absolutely right; it was on a snowy day of campaigning for him in Bury North that I received the phone call that would change my life, giving me my kidney cancer diagnosis. Despite that fact, I have since been back to Bury North; I am not saying that it was his bad luck—

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

It was not causation.

[Wes Streeting]

It was coincidence rather than causation, as my hon. Friend the cancer Minister says—although, given both our experiences, we will rethink our visit schedule to Bury.

On a serious note, my hon. Friend the Member for Bury North (Mr Frith) is absolutely right to make the link between poverty, particularly child poverty, and ill health. The last Labour Government lifted 400,000 children out of poverty; I am so proud to think that when in the first year of this Labour Government we chose to extend free school meals to half a million children from low-income families, with that one measure on one day we lifted 100,000 children out of poverty. That is the difference Labour Governments make, and that is how we will deliver not just an NHS fit for the future, but a fairer, more equal, more just society.

Rare Cancers Bill

Ashley Dalton Excerpts

Committee stage
Wednesday 2nd July 2025 Public Bill Committees

[Dr Caroline Johnson (Sleaford and North Hykeham) (Con)]

It is a pleasure to serve under your chairmanship, Mr Stuart. I congratulate the hon. Member for Edinburgh South West on bringing forward this very important piece of legislation. I declare an interest as a consultant paediatrician who has looked after a number of children with rare conditions such as teratoma, rhabdomyosarcoma, Wilms’ tumour and retinoblastoma, to name but a few.

One of the issues with rare cancers, which transposes to rare diseases in general, is that they are often diagnosed late, because people do not recognise that they have symptoms of a rare disease and their health professionals are not as familiar with them because they are rare. The presentation and diagnosis are then late and, as such, the treatment is more difficult. That is compounded further because there has been less research on those topics, so it is not clear what the best treatment for those conditions is. On top of that, the patient may have to travel very long distances to see a specialist who is familiar with the condition, adding both logistical difficulty and cost to that patient’s care.

Some steps are in place to try to improve the situation. The orphan drug regime gives market exclusivity for 10 years, and it provides for lower and refunded fees from the Medicines and Healthcare products Regulatory Agency for the services it provides. Nevertheless, it can still be non-commercially advantageous to put money into developing a drug that is going to be used on no more than a handful of people, however beneficial it is for the individuals concerned.

I welcome the Bill, but wish to make a couple of points. First, in principle it is best that trials are first broached with the patient by a member of their healthcare team. Of course, a member of any given healthcare team—I speak as one myself—will never be aware of all the trials available to all patients at any one time. I welcome the Lord O’Shaughnessy review—commissioned by the last Government and accepted by the current one—which talks about getting a consensus on how best patients can be informed of trials. I wonder whether we should have a system in which patients opt out of not the trial itself but being asked about trials. At the outset, they could be asked, “Would you like to receive information on trials—yes or no?”, so that more people can be aware of how they can contribute. When people are diagnosed with something rare, they often want to contribute to helping others who will come after them.

Will the Minister tell us more about the national cancer plan, which was consulted on earlier this year? I welcome the fact that the children and young people cancer taskforce, which was paused, is being reinstituted. Also, how will the Bill apply to repurposed drugs? Sometimes new medicines are developed for a particular condition, but we often find that medicines can be reformulated and used in a different way to provide a different form of treatment to help individuals with a different condition. How will that apply in respect of both the measures in the Bill and the O’Shaughnessy review?

As a paediatrician, I am very pleased that the Bill applies to children. Overall, I think the Bill is great. It offers hope for many in the future. Will the Minister say something about other rare conditions? As well as rare cancers, people get other rare conditions, and they are affected by the same challenges with research and treatment, and by delays in diagnosis and travel.

Overall, doctors are able to save people’s lives, and improve people’s lives, one at a time, but Parliament and research offer the opportunity to do that on a much bigger scale. I am very grateful to the hon. Member for Edinburgh South West for what he is doing today.

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

It is a pleasure to serve under your chairmanship, Mr Stuart. I congratulate my hon. Friend the Member for Edinburgh South West on his Bill reaching Committee stage. That is a huge achievement for any colleague, but especially for one who has served in this place for almost exactly a year to the day. The Government welcome contributions from Back Benchers, we welcome effective scrutiny from Committees, and we value the vital role that Parliament plays in holding us to account.

In April, my right hon. Friend the Prime Minister announced that clinical trials would be fast-tracked to accelerate the development of the medicines and therapies of the future. Through this new drive, patients will have improved access to new treatments and technologies. We see the Bill as contributing to that ambition. We want to go further for patients with rare cancers, and this legislation will act to incentivise recruitment, oversight and accessibility of rare cancer research, so that NHS patients are at the front of the queue for cutting-edge treatments.

Clause 1 will ensure our regulatory competitiveness. It places a duty on the Government to publish a review of the legislation around orphan drugs within three years of the Bill becoming an Act. The review will examine our legal framework and compare our approach to that of our international partners. We want the UK to lead the world in this space, as the prime destination for clinical research.

Clause 2 will raise the profile of research for rare cancers by placing a new duty on the Secretary of State for Health and Social Care to facilitate and otherwise promote research in this area. The Government want to give patients greater choice and control over their healthcare, and rare cancer patients should have access to research if they choose.

The clause also ensures that the Government will develop a bespoke registry service for rare cancers, to be delivered through the “Be Part of Research” programme—our groundbreaking research registry service provided by the National Institute for Health and Care Research—and that we will appoint a national specialty lead for rare cancers, which we will designate within the NIHR research delivery network, who will have oversight of the overall rare cancer studies portfolio in England.

The Government are committed to going further for rare cancer patients, and that means making clinical trials more accessible. Clause 3 will introduce an innovative solution to allow rare cancer patients to be contacted as quickly as possible about clinical research. The clause creates a new power to allow patient data to be shared from NHS England information systems.

[Dame Siobhain McDonagh (Mitcham and Morden) (Lab)]

Does the Minister agree that keeping a list of people with rare cancers is only any use as long as there are some drug trials? Last night we launched a first trial, in my sister’s memory, for glioblastoma, with every penny raised by people donating, holding bake sales and running marathons. Is that any way to tackle rare cancer?

[Ashley Dalton]

I congratulate my hon. Friend on the launch of the trial in her sister’s name. We do want to see more research and trials coming forward, particularly for rare cancers. She will be aware of the consortium that the Department has developed to work directly with the brain tumour community in particular, to improve the quality and number of research trials that come forward for funding.

[Josh Fenton-Glynn (Calder Valley) (Lab)]

Constituencies in Yorkshire, such as the one I represent, do particularly poorly with research funding—I think 5% of research funding for cancer trials goes to the area. With this Bill and a renewed focus on cancer, I hope we will look to expand the number of research-active hospitals to give people throughout the country a better chance.

[Ashley Dalton]

I should clarify that there is no regional specificity in the allocation of research funding. We welcome all funding bids for research on cancer and rare cancers from anywhere in the country, and I encourage them to come forward.

The new power in clause 3 to allow patient data from NHS England information systems to be shared will allow more patients to be contacted about existing trials. Practically, it will allow us to join up data from the national disease registration service with “Be Part of Research”. As I have said, we are encouraging people to bring forward more research proposals, all of which are considered.

For the first time, patients with a rare cancer could be automatically contacted about research opportunities that are relevant to them and offered innovative new treatments, which means rare cancer patients could have access to research at their fingertips. That is the kind of change that the Government support as part of the shift we are making from analogue to digital—one of the three shifts that will be covered in the 10-year plan that will be launched tomorrow, when more details will become clear.

Clause 4 covers the Bill’s territorial extent. Due to practical and legal differences between the nations, the devolved Governments did not wish to legislate in their individual countries. Our manifesto promised to reset our relationship with the devolved Governments, and we have developed the Bill with them. I am delighted that they expressed their support on Second Reading. Clauses 5 and 6 cover the Bill’s commencement and title. The Government are fully committed to supporting the Bill through the next stages so it can become the Rare Cancers Act 2025.

The shadow Minister talked about the national cancer plan, which I can confirm is being worked on. We have had over 11,000 representations on that plan, which will be published later this year, following the publication of the national 10-year plan for health tomorrow. The children and young people cancer taskforce was launched earlier this year and continues to meet, and has now ensured that young people and children’s voices are part of the taskforce.

[Clive Jones (Wokingham) (LD)]

When the national cancer strategy is published, I hope that part of it will focus on boosting the survival rates for rare cancers. Will the Minister confirm that that will be an important part of the strategy?

[Ashley Dalton]

I can confirm that the overall objective of the whole cancer plan will be saving lives and reducing the number of lives lost to cancer, including rare cancers. The plan will be published later this year.

It is important to note that the Bill is specific to cancer; there will be opportunities to discuss other rare conditions in the future. I thank my hon. Friend the Member for Edinburgh South West for presenting the Bill, and I pay tribute to the charities that are backing him, some of which I had the pleasure to meet recently to discuss further how the Government can better support people with rare cancers. Together, we will improve outcomes for people across our country, and I look forward to working with everybody to get that done.

[Dr Arthur]

I am grateful for all the contributions to debate. The charity partners carefully picked the Committee members, given their interest in this subject, and we can see the benefit of that.

I thank the hon. Member for South Antrim for his efforts to make sure that the legislation works in Northern Ireland. I am also grateful for the comments from the hon. Member for Wokingham and my hon. Friend the Member for Calder Valley, who both asked for more progress in this area generally.

Of course, I have to mention my hon. Friend the Member for Mitcham and Morden. I attended the reception yesterday evening and, first and foremost, it was a fantastic celebration of her sister’s fantastic life. We should be grateful for her. I wish Paul Mulholland and his team all the best with that trial. It really did fill me with hope to hear that update from him.

My hon. Friend the Member for Mitcham and Morden mentioned marathons, so at this point I have to mention my daughter, Ruth Arthur, who ran the marathon in Edinburgh for the Brain Tumour Charity and raised just over £3,000 in the memory of her grandfather. I am very proud of her.

I am grateful for the shadow Minister’s comments and the insight and depth of thinking she brought to the debate. One of the best things about this journey has been working with the DHSC team who are working on the cancer strategy, and seeing how much they care about getting this right. We have often reflected on the point that the shadow Minister made about diagnosis. Too often when we go to events in this place hosted by charities that include somebody with life experience, late diagnosis is where their story starts. It is often avoidable. It is fantastic that the DHSC cancer team acknowledge that. Hopefully our GPs in particular will get more support to make sure that the early signs are not missed and the dots are joined together. It is good to see the Minister nodding vigorously as I say that. I thank her for her leadership right across this policy area and for her support for the Bill in particular.

I thank all Committee members for coming along today and contributing, and I thank the civil servants who helped to draft the Bill. If it passes—and I really hope it does—it will incentivise and create an environment in which more research into rare cancers is fostered, potentially helping us to save, in the longer term, perhaps thousands of lives. What an aspiration that is. I once again commend the Bill to the Committee.

Clause 1 accordingly ordered to stand part of the Bill.

Clauses 2 to 6 ordered to stand part of the Bill.

Bill to be reported, without amendment.

Infant Feeding

Ashley Dalton Excerpts

Tuesday 1st July 2025 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

I congratulate the hon. Member on securing the debate. Through her leadership of the all-party parliamentary group for infant feeding, she is working to ensure that families across the country get the right support. I thank all hon. Members who have contributed—my hon. Friends the Members for Ribble Valley (Maya Ellis), for Altrincham and Sale West (Mr Rand), for South Derbyshire (Samantha Niblett) and for Brecon, Radnor and Cwm Tawe (David Chadwick), the hon. Members for Strangford (Jim Shannon) and for Exmouth and Exeter East (David Reed), and yourself, Madam Deputy Speaker.

The number of interventions and contributions has shown how important the issue is and how deeply it is felt across the House. The hon. Member for Chichester asked about the 10-year plan. I will not go into detail about what is in it, but—tick, tock—she does not have to wait long as the plan will be launched on Thursday morning.

I look forward to working with colleagues across the House and the wider health landscape on how we deliver the plan. In that plan, they will see that children’s early years are crucial to their development, health and life chances. That is why the Government are taking a mission-based approach to raising the healthiest generation of children ever and to ensuring that every child has a healthy, happy start to life.

[Dr Danny Chambers (Winchester) (LD)]

To reiterate the comments made by my hon. Friend the Member for Chichester (Jess Brown-Fuller) and the Minister about all children needing to have a healthy start, we cannot emphasise enough how important gestation and the first six months of life are. The factors that affect gestation and the first six months of life have a bigger impact on long-term health than anything we can do after that—any conscious decisions we make about our health are less impactful than what has happened to us during gestation and the first six months of life.

[Ashley Dalton]

I agree. The hon. Member will see in the 10-year plan and some of the investments we are making—for instance, to reduce the number of women smoking in pregnancy—that the Government recognise that.

We recognise that infant feeding is critical to a baby’s healthy growth and development, and we recognise the significant benefits of breastfeeding for both mothers and babies. We are fully committed to supporting families to breastfeed should they choose to do so. We know that most mothers want to breastfeed, but many stop before they would ideally like to. While it has been positive to see many more mothers continuing to breastfeed in recent years, we know that they can face complex barriers to achieving their infant feeding goals.

I recognise the concerns raised through the World Breastfeeding Trends Initiative report on the UK infant feeding policy landscape. Health is devolved, and I would like to commend Northern Ireland for its performance in this area, which was raised by the hon. Member for Strangford. However, we know through the report that England scores poorly, and we want to change that.

Families need quality services, trustworthy information, affordable options and systems that support them, not hinder them. Midwives and maternity services play a crucial role through the perinatal period in preparing and supporting families around infant feeding. We have committed to training thousands more midwives to better support women throughout their pregnancy and beyond, and there has been an increase of over 1,300 full-time equivalent midwives in the workforce since April 2024. We will publish a refreshed workforce plan to deliver the transformed health service that we will build over the next decade.

To drive forward improvement in maternity and neonatal services, we announced the launch of a national independent investigation into maternity and neonatal care. The investigation will recommend one set of national actions by December. A national maternity and neonatal taskforce, chaired by the Secretary of State, will then bring together independent experts to co-produce a national plan to drive improvement.

As families transition from maternity services to the community, it is important that they continue to receive the support they need, and health visitors are key to this. However, we know that health visitor numbers have decreased and there is variation in the level of services across the country, but it remains a universal service, and we are committed to that. In the plan for change, we committed to strengthening health visiting services so that all families can access their support.

We are investing in family hubs and the Start for Life programme, with £18.5 million this year to improve infant feeding support across 75 local authorities in England. Start for Life services are helping parents to access support where they need it and in a location that suits them, whether that is their home, their family hub, a hospital setting or through the many voluntary sector organisations that have been referred to today. Local authorities are working with partners to embed local infant feeding strategies, joining up services for seamless support and tailoring them to their community, with both universal and targeted support. They are building up the workforce, investing in infant feeding specialists, delivering high-quality training and expanding networks of peer supporters. Funding is also helping to train staff to identify complex needs early such as tongue-tie, and to offer timely support.

Although long-term evaluation is needed to understand the full impact of the programme, some promising findings are emerging. For example, ambitious multi-layered integrated infant feeding plans have led to increased breastfeeding rates in Coventry, and local health visitor data shows an increase in breastfeeding at six to eight weeks from 51% to 57% in just 18 months. We are also helping families across the UK to access breastfeeding support 24 hours a day through the National Breastfeeding Helpline.

[Jess Brown-Fuller]

The Minister highlights some brilliant examples that are a gold standard in care, but does she recognise that the process the Government are currently undertaking, with only half of local authorities being funded, means that we still end up with a patchwork level of support for new mothers? They do not know where they are meant to go, because it is different when they cross a county border.

[Ashley Dalton]

This is very much targeted through the family hub service and support for Start for Life, and through the universal health visiting offer and the National Breastfeeding Helpline we aim to offer all women who are breastfeeding the support that they need to do so. Parental leave has been touched on, and we know that supporting parents goes beyond services. Returning to work can influence how families choose to feed their babies, and in the plan to make work pay we have committed to a review of the parental leave system. As the hon. Member said, that review was launched by the Department for Business and Trade in the Chamber earlier today, and we are delighted to see that come forward.

I have spoken a lot about breastfeeding, but we absolutely recognise that when families cannot or choose not to breastfeed, it is vital that they get formula that is safe, nutritionally complete and affordable. Infant formula regulations and Competition and Markets Authority recommendations are important, but we know that many families are struggling to afford infant formula. We welcome the report from the CMA into the UK infant and follow-on formula market. It highlighted some of the issues that the hon. Member raised, in particular by noting that families rely on brand reputation and price as a proxy for quality, often choosing more expensive products. However, specific regulations require all infant formula to comply with robust nutritional and compositional standards, so that all infant formula sold on the UK market meets the nutritional needs of babies, regardless of the price or brand.

The CMA has made 11 recommendations to the Government, with four aims: to eliminate brand influence in healthcare settings; to provide better information for parents in retail settings; to strengthen labelling and advertising rules; and to ensure effective enforcement of regulations. The Government are supportive of what the CMA is trying to achieve. We want parents to be confident enough to choose lower-priced products, and for manufacturers and retailers to compete more on price. The CMA recommendations are UK wide. We are considering them alongside colleagues in the devolved Governments, and aim to have a UK-wide response available as soon as possible.

In conclusion, I thank the hon. Member for raising this important matter. The Government are committed to giving children the best start in life, and we do not underestimate the challenge of getting this right for families. We will continue to strengthen key services, build on good practice, and identify where we can have the greatest impact for families. Tomorrow I will meet the all-party group on babies, and I look forward to discussing these issues further with them.

Question put and agreed to.

Preventing Ill Health

Ashley Dalton Excerpts

Monday 30th June 2025 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

Today I am updating the House on some of the steps the Government will take to prevent and delay the onset of ill health, thereby restoring the means for people to lead a healthy life in places where it has become most difficult, and in turn reducing pressure on the NHS.

Healthy food standards

Obesity is one of the leading causes of ill health, costing the NHS £11.4 billion per year. Obesity rates have doubled in the last 30 years, and one in five children now leave primary school with obesity. In the 2023-24 school year, the prevalence of obesity was more than twice as high among children living in the most deprived areas as among children living in the least deprived areas. We will only tackle this successfully by taking a whole-of-society approach in which Government partners with industry to drive innovation and give people the power to make healthy choices.

We are announcing plans to work with the food industry to combat rising childhood obesity. Under new proposals, all large food businesses will be mandated to report against standardised metrics on healthier food sales by the end of this Parliament. This will set full transparency and accountability around the food that businesses are selling and encourage healthier products. Publishing this data annually will also support business investors to invest in healthier companies, by seeing which are performing well, encouraging further reformulation and development of new healthy foods.

Using that reporting, we will set new mandatory targets to increase the healthiness of sales in all communities, and will work with the Food Strategy Advisory Board on how to sequence the introduction of this policy. We want to use smarter regulation that makes the most of industry’s innovation and experience. Businesses will have the freedom to decide how they achieve the target—through improving products, introducing new healthier products, or changing loyalty schemes to make healthier products more available, and available to all. Public health experts believe small improvements to the average meal to reduce daily calorie intake by just 40-50 kcals could lead to 340,000 fewer children and two million fewer adults living with obesity.

We will engage with industry closely as we develop and consult on these proposals. We intend to work with all the devolved nations to ensure regulatory alignment for food businesses, and to achieve the maximum reduction of obesity we can across the UK.

NHS weight management services

We will be asking the NHS to do more to support our approach to prevention. To support people already living with obesity, we will double the number of patients referred to the NHS digital weight management programme, offering help proven to deliver results to 125,000 more people every year. Additionally, pioneering relationships with the biggest pharmaceutical companies will be brokered to expand access to weight loss services and treatments across the NHS, ensuring fairer access to weight loss drugs for those who cannot afford private prescriptions.

Vaccines

Vaccinations are, after access to clean water, the most effective public health intervention in the world for saving lives and promoting good health. However, uptake, particularly for children, has been in gradual decline for over a decade. Improving uptake will protect our children from infectious disease, reduce the burden on the NHS, and help consign some diseases to history, such as cervical cancer. To improve access to vaccinations, we are enhancing access to general practices for vaccinations, testing models to deliver vaccinations to some families through health visits, and expanding the role of community pharmacy, including offering catch-up vaccinations to protect against human papillomavirus.

We are expanding the NHS app, so that everyone knows what vaccinations they have had, what they need, and where to get them, at a time and location that meets their needs. Patients will be able to book jabs on the NHS app. Parents will be able to access a new vaccination hub on the NHS app, on behalf of their child, during 2026-27. Finally, we will launch the world’s first gonorrhoea immunisation programme to protect at-risk adults and help prevent the rise of antimicrobial resistance.

Health store app marketplace

We will build a health store app marketplace. We want to empower people to manage their own health and care, putting the ability to treat, manage and prevent conditions into the hands of our population. Successful adoption of digital health technologies across a range of clinical areas including mental health, cardiovascular health and musculoskeletal conditions may lead to improved patient outcomes, reduced waiting times and improved economic activity, by supporting people to stay in or return to work.

The health store will ensure that the products with the best evidence reach the hands of patients, irrespective of where you live across the country. The National Institute for Health and Care Excellence will play a crucial role in evaluating technologies, guaranteeing clinical effectiveness for patients and cost-effectiveness for the NHS. We will explore central funding for those technologies with an effective evidence base, as determined by NICE, making the NHS an attractive market that centrally supports innovation.

NHS points scheme

We are announcing a new NHS points scheme, which will be developed to reward people for taking positive actions to improve their health. Based on loyalty schemes popular with supermarkets, coffee shops and mobile banking apps, people could receive gift vouchers or discounts at their favourite high-street stores by simply upping their step count or making healthier food choices. We will shortly launch a market engagement process to start the conversation with business about what behaviours could be incentivised.

Musculoskeletal conditions

To further improve how patients in England engage with the NHS, and where it is clinically appropriate for them to do so, patients will be able bypass GPs to directly access specialist treatment using the NHS app, including treatment for MSK, mental health talking therapies, podiatry and audiology services. This will help deliver faster treatment for patients, while enabling GPs to focus on more complex cases by reducing pressure on them.

Tobacco

In addition to the measures set out, the Government are determined to put an end to the harms of tobacco. Smoking is still the biggest killer—it claims around 80,000 lives a year, causes one in four of all cancer deaths in England and kills up to two thirds of its long-term users. Our landmark Tobacco and Vapes Bill will help deliver our ambition for a smoke-free UK. It will create a smoke-free generation, gradually ending the sale of tobacco products across the country and breaking the cycle of addiction and disadvantage. The Bill will also strengthen the existing ban on smoking in public places. And while we know vapes are less harmful than smoking and can be an effective quit aid for smokers, we are doing more to protect children from the risks of harm and addiction. The Bill will stop vapes from being deliberately branded, promoted, and advertised to children to stop the next generation from becoming hooked on nicotine.

The full set of prevention measures, which will further set out how we deliver healthier, more prosperous lives for all, and help reduce health inequalities, build a stronger labour market and lower NHS demand, will be set out shortly in the Government’s 10-year health plan for England.

[HCWS756]

Rare Cancers Bill (Money)

Ashley Dalton Excerpts

Money resolution
Monday 30th June 2025 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

I beg to move,

That, for the purposes of any Act resulting from the Rare Cancers Bill, it is expedient to authorise the payment out of money provided by Parliament of:

(1) any expenditure incurred under or by virtue of the Act by the Secretary of State, and

(2) any increase attributable to the Act in the sums payable under or by virtue of any other Act out of money so provided.

I pay tribute to my hon. Friend the Member for Edinburgh South West (Dr Arthur) for bringing forward this important Bill. The Government support it, and are committed to making a real difference for patients with rare cancers.

[Jim Shannon (Strangford) (DUP)]

Just a quick one—I had hoped to speak to the Minister before she came to the Dispatch Box. In Northern Ireland, rare cancers account for a quarter of all cancer cases in both men and women. Will there be extra money set aside for Northern Ireland, where health is devolved, to deal with rare cancers? It is not just those who have rare cancers who have to deal with them; their families do, too. I ask that question of the Minister genuinely and respectfully.

[Ashley Dalton]

As the hon. Gentleman said, health is devolved. I am happy to write to him with the details of how we expect this private Member’s Bill to be implemented by the devolved Governments.

Question put and agreed to.

Health Inequalities: England

Ashley Dalton Excerpts

Wednesday 25th June 2025 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

Today I am updating the House on steps the Government will take to ensure the NHS is playing its part in tackling deep and long-standing inequalities in our country.

First, we are determined to better allocate funding to primary care providers in a way that reflects the additional complexity of delivering care in communities with high levels of ill health. GP practices serving more deprived areas receive on average 9.8% less funding per needs-adjusted patient than those in less deprived communities, despite having greater health needs and significantly higher patient-to-GP ratios. We recognise the importance of ensuring that funding for core services is distributed equitably between practices across the country. The Government will therefore commission a review of the Carr-Hill formula to ensure fairer allocation of resources to general practice. The Advisory Committee on Resource Allocation will also be asked to advise on how the setting of integrated care board allocations can better support the reduction of health inequalities to ensure that resources are targeted where they are most needed.

Secondly, I am confirming today that the Government intend to phase out deficit support funding starting from 2026-27. This funding was worth £2.2 billion in 2025-26. This change will help ensure that NHS funding is not simply directed to overspending systems, but instead reaches parts of the country where poor health outcomes and inequality are most concentrated. Details on how this change will be implemented will be set out in the medium-term planning information published later this year.

Thirdly, the Government will harness the role of the NHS as the nation’s largest employer by launching a new £5 million widening access demonstrators programme. In 2025-26, funding will be allocated to 10 integrated care systems to support 1,000 people nationally, from working-class communities disproportionately affected by unemployment and economic inactivity, into roles in health or social care. Participants will receive tailored training and employment support to help them move into employment or further training, with a focus on supporting individuals into permanent or longer-term employment opportunities, including in roles such as healthcare support and pharmacy support, or as administrative or facilities staff.

These measures form part of our commitment to delivering a fairer, more accountable, and more effective NHS, with resources and opportunities focused on the areas and communities that need them most.

[HCWS738]

Haemochromatosis Screening

Ashley Dalton Excerpts

Wednesday 25th June 2025 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

I thank my hon. Friend the Member for Na h-Eileanan an Iar (Torcuil Crichton) for securing this debate and for sharing his personal connection as someone who has haemochromatosis. In honour of World Haemochromatosis Week earlier this month, from 1 to 7 June, I pay tribute to the important work that my hon. Friend and our colleagues on the all-party parliamentary group are doing to raise awareness of genetic haemochromatosis.

As we have heard, genetic haemochromatosis can have debilitating consequences, including arthritis, joint pain, diabetes, fatigue, psychological or cognitive difficulties, skin conditions, menstrual problems, impotence, breathing and heart problems, abdominal pain, liver problems and hair loss. This genetic condition, which allows iron levels to build up in the body, particularly affects people of white northern European backgrounds.

It is estimated that as many as one in 150 people in England and Wales, one in 113 people in Scotland and one in 10 people in Northern Ireland are affected. Health is a devolved matter, and I am delighted to see Members from the devolved nations represented in this debate. I note the interventions from the hon. Member for Strangford (Jim Shannon), and from my hon. Friend the Member for Glasgow West (Patricia Ferguson), who is the Chair of the Scottish Affairs Committee.

All four nations in the UK are advised on screening matters by the same independent scientific advisory committee. The UK National Screening Committee is an independent scientific advisory committee that advises Ministers and the NHS in all four countries on all aspects of population and targeted screening, and supports implementation. Using research evidence, pilot programmes, economic evaluation, expert stakeholders and consultation, the UK NSC assesses the evidence for national screening programmes against a set of internationally recognised criteria. These cover the condition, the test, the treatment options, the effectiveness, the ethics and the acceptability of the screening programme. It is only where the offer to screen provides more good than harm that a screening programme is recommended.

The UK National Screening Committee reviewed the case for screening for genetic haemochromatosis in adults in 2021. After consideration, it recommended on balance against a national screening programme at that time. That was because although a faulty hereditary hemochromatosis protein gene—the HFE gene—is known to cause iron to build up, that does not happen to every person with the faulty gene. Screening could therefore result in people being told that they have a condition that would not go on to impact their lives, which may cause undue worry. Screening would identify people who may never experience symptoms.

A screening programme would be most relevant for this condition if pre-symptomatic treatment showed significant improvements in an individual’s prognosis. However, there is limited evidence on whether treatment is more effective in individuals without symptoms compared with those who have symptoms. Currently, there is no evidence that a screening programme is the best way of helping people with the condition.

However, the UK National Screening Committee keeps its decisions under review. It welcomes any new published peer-reviewed evidence that suggests the case for a new or modified screening programme via its annual call. Any individual or organisation can submit a topic to the UK NSC to consider a new screening programme or modification to an existing programme.

Haemochromatosis is one of the most common genetic diseases, and genetic testing is available. For patients in England who show unexplained iron overload suggestive of hereditary haemochromatosis, genetic testing is available at one of the seven genomic laboratories. Any healthcare professional who suspects their patient may have haemochromatosis can refer their patient for testing via their local NHS clinical genomic service.

As we have heard, the main way to treat the condition is venesection, which is a procedure to remove some of an individual’s blood. This may need to happen every week at first, but only two to four times a year once the condition is stable. For those who cannot have blood removed, chelation therapy is an option. This medicine reduces the amount of iron in a patient’s body. I know that the NHS Blood and Transplant service works with many patients who have genetic haemochromatosis. While some genetic haemochromatosis sufferers will not be well enough, many of these individuals are well enough, and like Lorraine, the constituent of my hon. Friend the Member for North Warwickshire and Bedworth (Rachel Taylor), offer to give blood as an alternative to venesection. Turning a life-altering condition into a lifesaving opportunity is to be commended. I take this opportunity to thank each and every patient who is able to do so and has opted for that route.

To conclude, I once again thank my hon. Friend the Member for Na h-Eileanan an Iar for bringing forward this important debate and every Member who has contributed. Let this be the beginning of a conversation about how we can best support people with haemochromatosis. The condition affects many in our constituencies, and this has been an important opportunity to highlight how we must support their diagnosis and treatment in the future.

Question put and agreed to.

Cervical Screening: Self-sampling

Ashley Dalton Excerpts

Tuesday 24th June 2025 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

I would like to inform the House that I have accepted the UK National Screening Committee’s recommendation to allow screening providers to offer self-sampling kits to under-screened individuals in the NHS cervical screening programme in England.

The NHS cervical screening programme in England provides all women and people with a cervix between the ages of 25 and 64 with the opportunity to be screened routinely to detect HPV infection or cervical abnormalities at an early, more treatable stage. The aim of the programme is to reduce the number of women who develop invasive cervical cancer and reduce the number who die from it.

Cervical screening does not test for cancer; it is a step before that helps to detect the risk of developing cervical cancer. This is because, since December 2019, the primary screen in the NHS cervical screening programme has been a test to detect high-risk HPV—hrHPV—which causes nearly all cervix cancers. A negative screen for hrHPV means that the chances of developing a cancer within five years are very small, as it can take around 10 years or more from the time hrHPV is caught to developing cervical cancer.

Research suggests that barriers to cervical screening attendance may include inaccessibility of appointments, anxiety and fear of discomfort and embarrassment, previous negative experiences of screening, cultural reasons, confidentiality concerns, and practical barriers such as time constraints and lack of transport or childcare. Currently, around three in 10 of the eligible population do not attend their cervical screening appointments. The change to the programme will allow service providers to offer these women a self-sample if they have not attended their appointment for six months or more following routine invitation. A self-sample that returns an hrHPV positive result will still require a clinical test to confirm the finding. However, trial evidence suggests that self-sampling will increase the numbers engaging with the screening programme.

It is important to note that, at this stage, the self-sample offer is being provided only to “under-screened” women —an under-screened individual is someone who is overdue for their routine cervical screening appointment by at least six months or has never attended. The reason that the offer is restricted to this group is because there is uncertainty about whether self-sampling is as good as clinician-taken sampling for those who regularly attend screening.

Self-sampling will help detect hrHPV, prevent cancer and save lives in those who currently do not access clinician-led screening. However, for those attending clinician testing, a shift to self-sampling might result in a programme that is not yet proven to be of equal efficacy. Further studies to consider whether self-sampling could be used across the whole population are being organised.

I would like to take this opportunity to thank the UK National Screening Committee for continuing to provide invaluable evidence-based expert advice on the introduction of new screening programmes and modifications to existing ones, and especially on achieving the right balance between benefit versus harms.

I would also like to pay tribute to and thank all those who work to deliver high-quality and safe screening across the country, and to encourage all those who are eligible for cervical screening to take up the offer of this lifesaving test.

[HCWS732]

Care Settings: Right to Maintain Contact

Ashley Dalton Excerpts

Tuesday 24th June 2025 Westminster Hall

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

Thank you, Ms Butler, for chairing this important debate at such short notice, and I thank my hon. Friend the Member for Liverpool Walton (Dan Carden) for securing it.

The Minister for Care, my hon. Friend the Member for Aberafan Maesteg (Stephen Kinnock), has asked me to pass on his apologies; he is unable to represent the Government in this debate as he is currently in session on the Mental Health Bill Committee. However, he joins me in thanking my hon. Friend the Member for Liverpool Walton not only for securing this debate, but for all the work he has done in advocating for relatives and friends to have the right to visit care home residents and patients in hospitals and hospices.

I also thank all those who have shared their personal stories and those who are in the Public Gallery today. I can say without hesitation that the Minister for Care and I agree with my hon. Friend on the importance of visiting in care settings. Contact with family and friends is a crucial part of a person’s care. Indeed, there is evidence that supporting people to be actively involved in their own care, treatment and support can improve outcomes and experiences for people receiving care. No one should be denied reasonable access to visitors when they are in a care home, a hospital, or a hospice. That includes receiving assistance from a care supporter or simply going for a walk with a family member or friend.

Before the covid-19 pandemic care homes, hospitals and hospices set visiting policies based on their specific local circumstances. During the pandemic, restrictions on visiting were implemented to prevent the spread of covid-19. Those restrictions were in response to clinical advice and were designed to protect people living in care or in hospital, who were often among the most vulnerable to the virus. Visiting and accompanying is one of the fundamental standards against which the Care Quality Commission assesses quality of care.

The Government recognise how important visiting is for the health and wellbeing of residents in care homes and patients in hospitals and hospices. We have monitored the position since the new fundamental standard was introduced in 2023. We know that the majority of health and care providers are facilitating visits and recognise their importance. The capacity tracker, a digital tool where adult social care providers self-report data, shows that 99.3% of care home providers are facilitating visits. That figure has been stable since September 2022. However, we also know that there are times when it is necessary for movement in and out of care settings to be temporarily restricted.

[Dr Johnson]

Can the Minister clarify what constitutes a visit in those circumstances? Would an hour’s visit once a week count, or is there a specific timeframe that qualifies?

[Ashley Dalton]

I do not have that data to hand, but I will make sure that it is provided to the shadow Minister afterwards.

While there is sometimes the need for temporary restrictions or modifications to minimise significant risks, the Government hope that such instances are a rarity. It is our aspiration to ensure that visiting policy and practice strike the best possible balance between individual wellbeing and public health needs. I have been really moved by, and taken note of, the evidence put forward by many Members that that may not always be the case.

The right hon. Member for Dwyfor Meirionnydd (Liz Saville Roberts) talked about her experience with her mother, and brought to life the value that family and friends bring to the emotional wellbeing of the person being cared for and how, as partners in care, they play a key role in delivering that care.

[Liz Saville Roberts]

I am interested to hear the Minister talk about visits, but I think the essence of what many of us have discussed today is that there is a role for family carers alongside salaried carers. We desperately urge the Government to find a way to bring that forward in law.

[Ashley Dalton]

I thank the right hon. Lady for that intervention, and it is noted. The hon. Member for Strangford (Jim Shannon) told the powerful story of his own mother-in-law and his experiences there, and spoke about the importance of family contact, specifically for children in health and social care settings. For the sake of clarity, regulation 9A does not cover children’s homes—there are other regulations for that. We are talking specifically about health and social care settings.

We heard powerful interventions from other Members, including my hon. Friend the Member for Altrincham and Sale West (Mr Rand). The Liberal Democrat spokesperson, the hon. Member for Mid Sussex (Alison Bennett), and the shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson), asked a series of questions: is regulation 9A sufficient? Can the CQC monitor an Act? What are the exceptional circumstances of regulation 9A? Who is making those decisions? What principle is being followed and how is it being properly monitored?

The Government are committed to understanding the current position and considering how it can be improved. That is why in April we launched a review of CQC regulation 9A: visiting and accompanying in care homes, hospitals and hospices. All the issues raised today will be explored as part of that review. We want the review to be thorough and will consider the experiences of those receiving care, their families and loved ones, providers and health experts, as well as information from the Care Quality Commission, the Local Government and Social Care Ombudsman and the Parliamentary and Health Service Ombudsman. To ensure that we get a wide range of views, we have also opened a call for evidence and are running focus groups, with the first one taking place later today.

The representations made in today’s debate will help to inform the review. I further thank all contributors, and assure them that their contributions have been noted. We are determined to understand whether the expectations set by the regulation are right and that its application in practice works in the best way across care homes, hospitals and hospices, and in relation to visiting and accompanying.

I can confirm for the hon. Member for Strangford that we will look at the experience of all UK nations, including Northern Ireland and Scotland, where the Care Reform (Scotland) Bill, which includes Anne’s law, was approved on 10 June. That law requires care providers to facilitate visits to care home residents and to identify an essential care supporter for each resident.

I can assure hon. Members that we will reflect on the points made here as we conduct the review. We will move fast and ensure that we do justice to this important issue. We need to understand the problems and gaps if we are to draw the right conclusions from the review. We are pressing on with evidence gathering and focus groups right now. We plan to publish the outcome of the review and any further steps in the autumn.